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Abstract 
Background: Uremic cardiomyopathy is a common cardiovascular complication of chronic kidney disease (CKD) 
characterized by left ventricular hypertrophy (LVH) and fibrosis enhancing the susceptibility of the heart to acute 
myocardial infarction. In the early stages of CKD, approximately 60% of patients are women. We aimed to investigate 
the influence of sex on the severity of uremic cardiomyopathy and the infarct size-limiting effect of ischemic precon-
ditioning (IPRE) in experimental CKD.
Methods: CKD was induced by 5/6 nephrectomy in 9-week-old male and female Wistar rats. Two months later, serum 
and urine laboratory parameters were measured to verify the development of CKD. Transthoracic echocardiography 
was performed to assess cardiac function and morphology. Cardiomyocyte hypertrophy and fibrosis were measured 
by histology. Left ventricular expression of A- and B-type natriuretic peptides (ANP and BNP) were measured by qRT-
PCR and circulating BNP level was measured by ELISA. In a subgroup of animals, hearts were perfused according to 
Langendorff and were subjected to 35 min global ischemia and 120 min reperfusion with or without IPRE (3 × 5 min 
I/R cycles applied before index ischemia). Then infarct size or phosphorylated and total forms of proteins related to 
the cardioprotective RISK (AKT, ERK1,2) and SAFE (STAT3) pathways were measured by Western blot.
Results: The severity of CKD was similar in males and females. However, CKD males developed more severe LVH com-
pared to females as assessed by echocardiography. Histology revealed cardiac fibrosis only in males in CKD. LV ANP 
expression was significantly increased due to CKD in both sexes, however, LV BNP and circulating BNP levels failed to 
significantly increase in CKD. In both sexes, IPRE significantly decreased the infarct size in both the sham-operated and 
CKD groups. IPRE significantly increased the phospho-STAT3/STAT3 ratio in sham-operated but not in CKD animals in 
both sexes. There were no significant differences in phospho-AKT/AKT and phospho-ERK1,2/ERK1,2 ratios between 
the groups.
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Introduction
Chronic kidney disease (CKD) is one of the most rap-
idly growing non-communicable diseases and an impor-
tant contributor to morbidity and mortality worldwide 
[1]. CKD is defined as abnormal renal structure and/
or function (glomerular filtration rate [GFR] < 60  mL/
min/1.73  m2) present for at least 3 months in patients [2]. 
In the general population, the global prevalence of CKD 
varies between 7 and 12% and is continuously increas-
ing due to the growing incidence of its most common 
primary causes, including hypertension and diabetes 
mellitus [3]. The age-standardized global prevalence of 
early CKD stages (G1–G3, GFR > 30  mL/min/1.73   m2) 
is higher in women than in men [4, 5]. Notably, a higher 
CKD prevalence among women was found not only for 
CKD stages with decreased GFR but also for albuminuria 
with normal GFR [1]. Mortality is higher among men in 
all stages of predialysis CKD, whereas mortality among 
patients on renal replacement therapy is similar for men 
and women [4, 5].
CKD and end-stage renal disease (ESRD) patients have 
a 5- to 10-fold higher risk for developing cardiovascular 
diseases (CVDs) compared to the age-matched control 
population [6]. Large population studies have reported 
that all stages of CKD predispose to premature death, 
mainly from cardiovascular diseases (CVDs), and this is 
not restricted to ESRD [7]. Interestingly, the incidence of 
cardiovascular mortality is much higher in CKD patients 
at stages G2 and G3 than in ESRD patients [6, 8]. Ure-
mic cardiomyopathy (i.e., type 4 cardiorenal syndrome) 
is defined as the structural, functional, and electro-
physiological remodeling of the heart in CKD [9, 10]. It 
is characterized by left ventricular hypertrophy (LVH) 
and fibrosis, diastolic and systolic dysfunction, capillary 
rarefaction, and enhanced susceptibility to further inju-
ries, including acute myocardial infarction (AMI) and 
arrhythmias [9]. Epidemiological and imaging studies 
proved that the primary manifestation of uremic car-
diomyopathy is LVH and its prevalence increases with 
the progression of CKD (stage G3: 31%, G4: 50%, G5 
and ESRD: 90%, respectively) [11–13]. The severity and 
persistence of LVH are strongly associated with car-
diovascular events and mortality risk in CKD and ESRD 
patients [6]. Macrovascular disease seems to be more 
important in the early stages of CKD, and microvascular 
injury could play a major role in the late stages of CKD 
[7]. Therefore, AMI is a common cause of death in the 
early stages of CKD. In contrast, ESRD patients are more 
prone to sudden cardiac death due to arrhythmias and 
heart failure related to LVH, coronary calcification, and 
electrolyte disturbances [7].
One of the most powerful endogenous adaptive mech-
anisms of the heart is ischemic preconditioning (IPRE), 
in which brief cycles of myocardial ischemia and reper-
fusion periods significantly enhances the ability of the 
heart to withstand a subsequent prolonged ischemic 
injury (i.e., AMI) [14]. Preinfarction angina, warm-up 
phenomenon, and transluminal coronary angioplasty are 
considered clinical equivalents of IPRE [14]. Although 
IPRE confers remarkable cardioprotection in a variety of 
Conclusion: The infarct size-limiting effect of IPRE was preserved in both sexes in CKD despite the more severe 
uremic cardiomyopathy in male CKD rats. Further research is needed to identify crucial molecular mechanisms in the 
cardioprotective effect of IPRE in CKD.
Highlights 
1. There was no difference in the severity of chronic kidney disease (CKD) between male and female rats based on 
serum urea and creatinine levels as well as creatinine clearance.
2. As compared to females, males developed a more severe uremic cardiomyopathy characterized by left ventricu-
lar hypertrophy and fibrosis in CKD based on echocardiography and histology.
3. Following ischemia/reperfusion, infarct size was significantly smaller in females than in males, both in the sham-
operated and CKD groups.
4. The infarct size-limiting effect of ischemic preconditioning (IPRE) was preserved in both sexes in CKD despite 
the more severe uremic cardiomyopathy in male CKD rats.
5. IPRE significantly increased the phospho-STAT3/STAT3 ratio in sham-operated, but not in CKD animals in 
both sexes.
Keywords: Uremic cardiomyopathy, Cardioprotection, Left ventricular hypertrophy and fibrosis, Diastolic dysfunction, 
Chronic renal failure, Ischemic preconditioning, Infarct size, Myocardial function, Reperfusion-induced salvage kinase 
(RISK) pathway, Survivor activating factor enhancement (SAFE) pathway
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species [15, 16], including humans [17–19], we and oth-
ers have shown in pre-clinical and clinical studies that its 
effectiveness is attenuated by age [14] and some co-mor-
bidities, such as hypercholesterolemia [18, 20, 21] and 
diabetes mellitus [22–24]. However, some pre-clinical 
studies on CKD using male animals suggest that despite 
the complex systemic metabolic changes in CKD, cardio-
protection by IPRE is still preserved. Byrne et al. reported 
that IPRE confers its cardioprotective effect via the RISK 
and SAFE pathways after 4 weeks of 5/6 nephrectomy or 
adenine-enriched diet-induced subacute renal failure in 
male rats [25]. However, experimental models of short-
term renal failure may not correctly reflect the clinical 
situation because CKD frequently remains undiagnosed 
for a long time [26, 27]. Our research group found that 
IPRE still reduces the infarct size in prolonged uremia in 
male rats 30  weeks after 5/6 nephrectomy [28]. Never-
theless, so far, there is no experimental data available on 
ischemia/reperfusion (I/R) injury or the effects of IPRE 
in CKD in females. Therefore, we aimed to compare the 
severity of I/R injury and the potential cardioprotective 
effects of IPRE in CKD in male and female rats.
Materials and methods
This investigation conformed to the National Institutes 
of Health Guide for the Care and Use of Laboratory Ani-
mals (NIH Publication No. 85-23, Revised 1996) and was 
approved by the Animal Research Ethics Committee of 
Csongrád County (XV.1181/2013-2018) and the Univer-
sity of Szeged in Hungary. All institutional and national 
guidelines for the care and use of laboratory animals were 
followed.
Animals
A total of 160 age-matched female (n = 110, 9 weeks old, 
180–200  g) and male (n = 86, 9-weeks old, 300–350  g) 
Wistar rats were used in this study. A total of 90 animals 
(46 males and 44 females) underwent a sham operation, 
and a total of 106 animals (40 males and 66 females) 
received 5/6 nephrectomy to induce CKD. After the 
operations, 4 animals (2 males and 2 females) died in 
the CKD groups. Animals were housed in pairs in indi-
vidually ventilated cages (Sealsafe IVC system, Italy) and 
were maintained in a temperature-controlled room with 
12-h:12-h light/dark cycles throughout the study. Stand-
ard rat chow and tap water were supplied ad libitum.
Experimental setup
Experimental CKD was induced by 5/6 nephrectomy. 
Animals underwent sham operation or 5/6 nephrec-
tomy in two phases. After the operations, both groups 
were followed up for 9 weeks (Fig. 1). At week 8, cardiac 
morphology and function were assessed by transthoracic 
echocardiography in a subgroup of animals (n = 26 males 
[15 sham and 11 CKD] and 23 females [10 sham and 13 
CKD]), (Fig. 1). Moreover, a subgroup of animals (n = 25 
males [11 sham and 14 CKD] and n = 22 females [10 sham 
and 12 CKD]) was placed into metabolic cages at week 
8 for 24 h to estimate creatinine clearance and measure 
urine creatinine and protein levels (Fig.  1). At week 9, 
blood was collected from the thoracic aorta (n = 27 males 
[14 sham and 13 CKD] and n = 26 females [12 sham and 
14 CKD]), then serum urea, creatinine, ion levels, and 
plasma level of B-type natriuretic peptide (BNP) were 
measured. At the end of the follow-up period at week 9, 
hearts were isolated, then the blood was washed out in 
Krebs–Henseleit solution and hearts were used for his-
tology and qRT-PCR measurements or perfused ex vivo 
by oxygenated Krebs–Henseleit solution, according to 
Langendorff. In the case of ex vivo perfusions, the men-
strual cycle of the female rats was determined 12 h before 
the termination. To assess the cardioprotective effect of 
IPRE of sham-operated and CKD animals, the perfused 
hearts were subjected to global ischemia/reperfusion 
(I/R) with or without ischemic preconditioning proto-
col (IPRE) (Fig. 1). Coronary flow (CF) was measured (i) 
10 min after heart cannulation (CF10’), (ii) immediately 
after the global ischemia in the 80th minute of the perfu-
sion protocol (CF80’), and (iii) at the end of the reperfu-
sion in the 200th minute of the protocol (CF200’) (Fig. 1). 
At the end of the appropriate perfusion protocol, the 
infarcted area was delineated using the triphenyl-tetra-
zolium chloride (TTC) staining method in a subgroup of 
animals (n = 43 in males and 57 in females). In another 
subgroup of animals, right and left ventricles were sepa-
rated at the end of the perfusion protocols, and the LV 
samples were prepared for biochemical measurements 
(n = 24 males and n = 28 females) (Fig.  1). In this sub-
group, left ventricular expression of phosphorylated and 
total proteins of STAT3, AKT, and ERK-1,2 were meas-
ured by Western blot technique (Fig. 1).
5/6 Nephrectomy
Sham operation and 5/6 nephrectomy were performed 
in two phases as described previously [28, 29] (Fig.  1). 
Anesthesia was induced by intraperitoneal injection of 
pentobarbital sodium (Euthasol; 40  mg/kg; Produlab 
Pharma b.v., Raamsdonksveer, The Netherlands). At the 
first operation, two pieces of sutures (5–0 Mersilk; Ethi-
con, Somerville, NJ) were placed around both poles of 
the left kidney, approximately at the 1/3 position. Then 
the sutures were gently ligated around the kidney. 1/3 
of the kidney was excised right beyond the ligatures on 
both ends. Accidental bleeding was alleviated by thermal 
cauterization. One week after the first operation, animals 
were anesthetized, and the right kidney was freed from 
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the surrounding adipose tissue and the renal capsule. 
It was then gently pulled out of the incision. The adre-
nal gland was gently freed and was placed back into the 
abdominal cavity. The renal blood vessels and the ureter 
were ligated, and the whole right kidney was removed. 
During sham operations, renal capsules were removed. 
After the surgeries, the incision was closed with run-
ning sutures and povidone–iodine (Betadine solution, 
100  mg povidone–iodine complex/mL, Egis Zrt, Buda-
pest, Hungary) was applied on the surface of the skin. 
As a postoperative medication, nalbuphine hydrochlo-
ride was administered for 4  days (sc. 0.3  mg/kg Nalbu-
fin 10 mg/mL injection; TEVA Zrt, Debrecen, Hungary, 
twice in the first two postoperative days and once in the 
third and fourth postoperative days). Enrofloxacin anti-
biotics (Enroxil 75  mg tablets solved in drinking water 
[3.5  mg/L]; Krka, Slovenia) were administered in tap 
water for 4 days after both surgeries.
Fig. 1 Protocol figure. Male and female Wistar rats underwent sham operation or 5/6 nephrectomy in 2 phases to induce chronic kidney 
disease (CKD). First, 2/3 of the left kidney was ligated and excised (Op1). One week later, the right kidney was removed (Op2). Corresponding 
time-matched sham operations were performed in the sham groups. At week 8, cardiac morphology and function were assessed by transthoracic 
echocardiography (echo) in a subgroup of animals. In this week, a subgroup of the animals was placed for 24 h into metabolic cages to collect 
urine for determination of urine creatinine and protein levels. At week 9, rats were anesthetized, and blood was collected from the thoracic aorta 
to measure serum urea and creatinine levels (blood). In this week, blood pressure was also measured in a subgroup of animals (BP). Hearts were 
then an isolated used for histology (histo) and qRT-PCR (qPCR) measurements or perfused according to Langendorff, the perfused hearts were 
subjected to global ischemia/reperfusion (I/R) with or without ischemic preconditioning protocol (IPRE, 3 × 5 min I/R cycles). Coronary flow (CF) 
was measured at the 10th, 80th, and 200th minutes of the perfusion protocol (CF10’, CF80’, and CF200’, respectively). At the end of the perfusion 
protocol, hearts were collected for infarct size (IS) or Western blot (WB) measurements
Page 5 of 20Sárközy et al. Biol Sex Differ           (2021) 12:49  
Transthoracic echocardiography
Cardiac morphology and function were assessed by tran-
sthoracic echocardiography at week 8 as described pre-
viously [30–32] (Fig.  1). Briefly, rats were anesthetized 
with 2% isoflurane (Forane, AESICA, Queenborough 
Limited Kent, UK). Then, the chest was shaved, and the 
rat was placed in a supine position onto a heating pad. 
Two-dimensional, M-mode, Doppler, tissue Doppler and 
4 chamber-view echocardiographic examinations were 
performed in accordance with the criteria of the Ameri-
can Society of Echocardiography with a Vivid IQ ultra-
sound system (General Electric Medical Systems) using a 
phased array 5.0–11 MHz transducer (GE 12S-RS probe). 
Data of three consecutive heart cycles were analyzed 
(EchoPac Dimension software; General Electric Medi-
cal Systems) by an experienced investigator in a blinded 
manner. The mean values of three measurements were 
calculated and used for statistical evaluation.
Serum and urine laboratory parameters
At week 8, a subgroup of animals was placed into meta-
bolic cages (Tecniplast, Italy) for 24 h to collect urine for 
the measurement of creatinine and protein levels. Urine 
creatinine and urine protein levels were measured by 
standard laboratory methods as described previously [28, 
29] to verify the development of CKD (Fig. 1).
Blood was collected from the thoracic aorta at week 9 
to measure serum urea (carbamide) and creatinine lev-
els to verify the development of CKD. Serum urea and 
creatinine levels were quantified by kinetic UV method 
using urease and glutamate dehydrogenase enzymes and 
Jaffe method, respectively [28, 29] (Fig. 1). The reagents 
and the platform analyzers were from Roche Diagnostics 
(Mannheim, Germany).
Creatinine clearance, an indicator of renal func-
tion, was calculated according to the standard for-
mula (urine creatinine concentration [μM] × urine 
volume for 24  h [mL])/(serum creatinine concentration 
[μM] × 24 × 60  min) as described previously [28, 29] 
(Fig. 1). Urine volume and urine creatinine concentration 
were measured at week 8, and serum creatinine concen-
tration was determined at week 9.
Plasma BNP levels
Plasma BNP level was determined as a marker of myo-
cardial stretch in CKD at week 9 (n = 6–7, Fig.  1). The 
levels of BNP in the blood plasma of sham-operated and 
CKD rats were determined with enzyme-linked immu-
nosorbent assay (ELISA) kits recognizing rat peptides 
(Sigma-Aldrich, USA, #RAB0386) in accordance with the 
manufacturer’s instructions.
Blood pressure measurement
To measure arterial blood pressure, a 1.6 F, polyam-
ide, pressure catheter (Scisense Systems Inc., London, 
ON, Canada) was inserted into the left femoral artery 
at week 9 under anesthesia (Euthasol; 40 mg/kg; Produ-
lab Pharma b.v., Raamsdonksveer, The Netherlands) in a 
separated subgroup of animals (n = 6–11) as described 
previously [29, 33] (Fig. 1). Blood pressure measurements 
were performed between 09:00 and 14:00 hours.
Histological measurements on hematoxylin–eosin 
and picrosirius red/fast green‑stained sections
In a subgroup of the animals (n = 6–9), 5-μm-thick 
sections from formalin-fixed paraffin-embedded tis-
sue blocks taken transversely from the subvalvular 
areas of the left ventricles were stained with hematoxy-
lin–eosin (HE) or picrosirius red/fast green (PSFG) as 
described previously [29–31] (Fig.  1). Histological sec-
tions were scanned with a Pannoramic Midi II scanner 
(3D-Histech, Hungary) and digital images at the magni-
fication of × 10, × 40 and × 100 were captured. To verify 
the development of left ventricular hypertrophy, cardio-
myocyte perimeter was measured in 100 selected, longi-
tudinally oriented, mono-nucleated cardiomyocytes on 
digital images from a single left ventricular transverse 
slide. [29–31].
Cardiac fibrosis was assessed on PSFG slides with an 
in-house developed program as described previously 
[29–31]. Briefly, this program determines the proportion 
of red pixels of heart sections using two simple color fil-
ters. For each red–green–blue (RGB) pixel, the program 
calculates the color of the pixel in hue–saturation–lumi-
nance (HSL) color space. The first filter is used for detect-
ing red portions of the image. The second filter excludes 
any white (empty) or light grey (residual dirt on the slide) 
pixel from further processing using a simple RGB thresh-
old. In this way, the program groups each pixel into one 
of two sets: pixels considered red and pixels considered 
green but neither white, nor grey. Red pixels in the first 
set represent collagen content and fibrosis. Green pix-
els in the second set correspond to cardiac muscle. The 
mean values of 10 representative images were calculated 
and used for statistical evaluation in the case of each left 
ventricular slide. Medium-size vessels and their perivas-
cular connective tissue sheet, the subepicardial and sub-
endocardial areas were avoided as much as possible.
qRT‑PCR measurements
Quantitative RT-PCR was performed with gene-specific 
primers to monitor left ventricular mRNA expression 
at week 9 [29]. Total RNA was isolated from left ven-
tricles (n = 7–11) with 5:1 mixture of Biozol total RNA 
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extraction reagent (Bioflux, China) and chloroform 
(Molar Chemicals, Hungary). The RNA containing aque-
ous phase was further precipitated with isopropanol 
(Molar Chemicals, Hungary). RNA concentration and 
purity were determined by spectrophotometric measure-
ment with NanoDrop One (Thermo Scientific, Waltham, 
USA). Then 100 μg of total RNA was reverse transcribed 
using iScript™ cDNA Synthesis Kit (BioRad Laboratories 
Inc., USA). Specific primers (Nppa: A-type natriuretic 
peptide, #qRnoCED0006216 and Nppb: B-type natriu-
retic peptide, #qRnoCED0001541) and SsoAdvanced™ 
Universal SYBR® Green Supermix (BioRad Laboratories 
Inc., USA) were used according to the manufacturer’s 
instructions. Peptidyl-prolyl isomerase A (Ppia, forward 
primer sequence: tgctggaccaaacacaaatg, reverse primer 
sequence: caccttcccaaagaccacat) was used as a house 
keeping control gene for normalization.
Vaginal smear and menstrual cycle
The menstrual cycle of the female animals was tested 
before heart perfusion protocols because the fluctua-
tion of estrogen and progesterone levels may influence 
the infarct size and protein expression levels. We aimed 
to select the female rats in the di-estrus phase in which 
the hormone levels are the lowest. The menstrual cycle 
was determined 12  h before the heart perfusions. For 
vaginal smear collection, a cotton earbud was used after 
physiologic saline slosh. Vaginal smear was put on glass 
slides, stained by Giemsa solution, and fixed with a mix-
ture of 20% alcohol and diethyl-ether in a 1:9 ratio. The 
slides were examined by light microscopy under × 40 
magnification. The amount of vaginal epithelial cells, 
their morphology, and the presence of lymphocytes were 
evaluated.
Ex vivo cardiac perfusions and ischemic preconditioning
At week 9, rats were anesthetized, and hearts were iso-
lated and perfused at 37  °C according to Langendorff 
with oxygenated Krebs–Henseleit buffer as previously 
described [28, 34]. Hearts from the sham-operated and 
the CKD groups were further divided into two subgroups 
and subjected to either a non-conditioning or precon-
ditioning perfusion protocol, respectively (Fig.  1). Non-
conditioned hearts were subjected to time-matched 
(45  min) aerobic perfusion followed by 35-min global 
I/R. Preconditioned hearts were subjected to 5  min of 
ischemia and 5 min reperfusion in 3 intermittent cycles 
before the 35  min of global index ischemia. Coronary 
flow was measured at the 10th, 80th, and 200th min of 
the perfusion protocol, respectively. At the end of the 2-h 
reperfusion, the hearts were weighed and used for infarct 
size or biochemical measurements. Body, lung, and kid-
ney weights were also measured.
Infarct size determination
After the end of reperfusion, in a subgroup of hearts, 
atria were removed, and the total ventricles were used 
to determine the infarcted area as described previously 
[34, 35]. Briefly, frozen ventricles were cut to 7–8 equal 
slices and placed into triphenyl-tetrazolium chloride 
solution (Sigma-Aldrich, Saint Louis, MO, USA) for 
10 min at 37 °C followed by a 10 min formaldehyde fix-
ation and phosphate buffer washing steps. As a result, 
survived areas were red-stained while the necrotic area 
remained pale. Digitalized images from the stained 
heart slices were evaluated with planimetry, and the 
amount of myocardial necrosis was expressed as infarct 
size/area at risk % as described previously [36].
Western blot
At the end of the 2 h reperfusion, hearts were separated 
for left and right ventricles in a subgroup of animals. 
Left ventricles were used for standard Western blot 
measurements to investigate gene expression changes 
at the protein level in the case of phospho-AKT, AKT, 
phospho-ERK1,2, ERK1,2, phospho-STAT3, STAT3 
with GAPDH loading background. Left ventricular 
tissue samples (n = 52) were homogenized with an 
ultrasonicator (UP100H Hielscher, Teltow, Germany) 
in Radio Immunoprecipitation Assay (RIPA) buffer 
(50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.5% sodium 
deoxycholate, 5  mM ethylenediamine tetra-acetic acid 
(EDTA), 0.1% sodium dodecyl sulphate, 1% NP-40 (Cell 
Signaling, Carlsbad, CA, USA) supplemented with pro-
tease inhibitor cocktail and phosphatase inhibitors phe-
nylmethylsulfonyl fluoride (PMSF) and sodium fluoride 
(NaF, Sigma, Saint Louis, USA). The crude homogenates 
were centrifuged at 15,000×g for 30 min at 4 °C. After 
quantification of protein concentrations of the super-
natants using BCA Protein Assay Kit (Pierce, Rockford, 
IL, USA), 25 μg of reduced and denatured protein was 
loaded. Then sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS-PAGE) was performed (10% 
gel, 90  V, 2  h in case of AKT, ERK1,2, STAT3), which 
was followed by transfer of proteins onto a nitrocel-
lulose membrane (20% methanol, 35  V, 2  h in case of 
AKT, ERK1,2, STAT3). The efficacy of transfer was 
checked using Ponceau staining. The membranes were 
cut horizontally into parts corresponding to the molec-
ular weights of AKT, ERK1,2, STAT3, and GAPDH and 
were blocked for 1 h in 5% (w/v) bovine serum albumin 
(BSA) or milk at room temperature and then incubated 
with primary antibodies (Cell Signaling, Carlsbad, CA, 
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USA) in the concentrations of 1:1000 against phospho-
AKT (Ser473, #4060), AKT (#9272), phospho-ERK1,2 
(Tr202/Tyr204, #9101 S), ERK1,2 (#9102), phospho-
STAT3 (Ser727; #9134) overnight, 4  °C, 5% BSA), 
and 1:5000 against GAPDH (#2118, overnight, 4  °C, 
1% BSA). Then, the membranes were incubated with 
IRDye® 800CW Goat Anti-Rabbit and IRDye® 680RD 
Goat Anti-Mouse secondary antibody (Li-Cor) for 1  h 
at room temperature in 5% BSA. Fluorescent signals 
were detected by Odyssey CLx, and digital images were 
analyzed and evaluated by Quantity One Software [37].
Statistical analysis
Statistical analysis was performed using Sigmaplot 12.0 
for Windows (Systat Sofware Inc). All values are pre-
sented as mean ± SEM. Specific sample numbers used for 
measurements are described in the corresponding figure 
legend. Baseline and different follow-up data, including 
serum metabolite and ion concentrations, plasma BNP 
level, and echocardiographic, histologic and qRT-PCR 
data were compared using two-way analysis of variance 
(ANOVA). Infarct size and Western blot measurement 
data were compared using three-way ANOVA. Holm–
Sidak test was used as a post hoc test.
Results
Males and females develop a similar severity of chronic 
kidney disease based on routine laboratory parameters
To verify the development of CKD induced by 
5/6-nephrectomy, concentrations of several serum and 
urine metabolites were measured at week 9. The serum 
urea and creatinine levels were similar in the sham-oper-
ated males and females (p = 0.388 and p = 0.709, Fig. 2A 
and B, respectively). The serum urea levels showed a sig-
nificant increase to 200% in both sexes in 5/6-nephrec-
tomized rats compared to the sham-operated animals 
(*p < 0.001 in both sexes, Fig.  2A). The serum creati-
nine levels were significantly higher in male and female 
Fig. 2 The effects of sex and CKD on laboratory markers. A Serum urea concentration; B serum creatinine concentration; C creatinine clearance 
was calculated from urine volume, urine and serum creatinine concentrations according to the formula: urine creatinine concentration [μM] × urine 
volume for 24 h [mL])/(serum creatinine concentration [μM] × 24 × 60 min¥; D urine protein concentration; E serum cholesterol concentration, and 
F serum triglyceride concentration. Urine volume and urine creatinine concentration were measured at week 8, and serum creatinine concentration 
was determined at week 9. Values are means ± SEM, n = 12–14 for serum parameters (sham male: n = 13, CKD male: n = 14, sham female: n = 12, 
and CKD female: n = 14), and n = 10–14 for urine parameters and creatinine clearance (sham male: n = 11, CKD male: n = 14, sham female: n = 10, 
and CKD female: n = 12), *p < 0.05, CKD vs. sham-operated groups, #p < 0.05, females vs. males, p-values refer to two-way ANOVA (Holm–Sidak post 
hoc test)
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5/6-nephrectomized rats (253%, *p < 0.001 and 217%, 
*p < 0.001, respectively) than in the sex-matched sham-
operated animals (Fig. 2B). The creatinine clearance was 
significantly lower (57%) in the sham-operated females 
than in the sham-operated males (#p < 0.001), prob-
ably due to the smaller body weight and muscle mass 
of the females (Fig. 2C). Moreover, the creatinine clear-
ance showed a significant decrease in male and female 
5/6-nephrectomized rats (56%, *p < 0.001 and 59%, 
*p = 0.031, respectively) compared to the sex-matched 
sham-operated animals showing a similarly decreased 
renal function in both sexes (Fig. 2C). The urine protein 
concentration was significantly lower (36%) in the sham-
operated females than males (#p = 0.010, Fig. 2D). Urine 
protein concentration was significantly increased in 
male and female 5/6-nephrectomized rats (to 930% and 
640%, respectively, *p < 0.001 in both sexes) compared to 
their sex-matched controls (Fig.  2D). Serum cholesterol 
and triglyceride levels were measured as cardiovascu-
lar risk factors. Serum cholesterol levels were similar in 
the sham-operated animals (p = 0.352); however, serum 
triglyceride level was significantly lower in the sham-
operated females than males (42%, #p < 0.001) (Fig.  2E, 
F). Serum cholesterol levels were significantly elevated in 
male and female 5/6-nephrectomized rats (to 158% and 
139%, respectively, *p < 0.001 in both sexes) compared 
to the sex-matched sham-operated animals (Fig.  1E). 
Serum triglyceride levels were significantly reduced (to 
48%) in female 5/6-nephrectomized rats compared to 
5/6-nephrectomized males (#p < 0.001, Fig.  2E). Lower 
serum triglyceride levels in females irrespective of CKD 
might refer to their reduced cardiovascular risk as com-
pared to males.
Fig. 3 The effects of sex and CKD on echocardiographic parameters and blood pressure. A Representative M-mode images; B anterior wall 
thicknesses in systole (AWTs); C anterior wall thicknesses in diastole (AWTd); D mean arterial blood pressure (MAP); E ejection fraction (EF); F E/e′ 
ratio; G isovolumic relaxation time (IVRT) measured at week 9. Values are means ± SEM, n = 10–15 for echocardiography (sham male: n = 15, CKD 
male: n = 11, sham female: n = 10, and CKD female: n = 13) and n = 6–11 for blood pressure measurement (sham male: n = 10, CKD male: n = 11, 
sham female: n = 6, and CKD female: n = 8), *p < 0.05, CKD vs. sham-operated groups, #p < 0.05, females vs. males p-values refer to two-way ANOVA 
(Holm–Sidak post hoc test)
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Uremic cardiomyopathy is more severe in males 
than in females
Males develop more severe LVH and diastolic dysfunction 
in CKD than females
Transthoracic echocardiography was performed at week 
8 to investigate whether CKD development leads to 
similar myocardial morphologic and functional altera-
tions in both sexes. Most of the left ventricular systolic 
and diastolic wall thicknesses were not significantly dif-
ferent between males and females in the sham-operated 
groups (Fig.  3A–C, Table  1). Among wall thicknesses, 
the diastolic anterior and septal wall thickness were sig-
nificantly decreased (to 82% and 84%, respectively) in 
the sham-operated females compared to sham-operated 
males (#p < 0.001, Fig. 3 and Table 1) due to their smaller 
heart size. Notably, the systolic septal and diastolic infe-
rior wall thicknesses showed a trend toward a decrease in 
the sham-operated females compared to sham-operated 
males (Table  1). The left ventricular end-diastolic and 
end-systolic diameters were significantly reduced (to 92% 
and 61%, respectively) in sham-operated females com-
pared to sham-operated males, probably corresponding 
to the smaller body and heart size of females (Table  1). 
In response to CKD, systolic and diastolic anterior wall 
thicknesses were significantly increased in both sexes (to 
129%, and 134% in males and 117% and 116% in females, 
respectively) compared to the sex-matched sham-oper-
ated animals (*p < 0.001 for both sexes and walls, Fig. 3B, 
C). In CKD males, diastolic inferior, posterior, and sep-
tal, and systolic septal wall thicknesses were significantly 
increased compared to those of sham-operated males (to 
130%, 128%, 124%, and 122%, respectively) (Table 1). In 
contrast, CKD females showed a smaller relative increase 
in fewer wall thicknesses than CKD males (Fig.  3A–C 
and Table 1). In CKD females, diastolic inferior, diastolic 
and systolic septal wall thicknesses were significantly 
increased compared to those of sham-operated females 
(to 118%, 111%, and 109%, respectively) (Table  1). Left 
ventricular end-diastolic and end-systolic diameters 
showed no significant difference in response to CKD in 
either sex. However, left ventricular end-systolic diameter 
showed a trend toward a decrease in males in response 
to CKD, probably due to the more severe LVH (Table 1). 
Left ventricular end-diastolic volume, stroke volume, and 
cardiac output were significantly decreased in CKD males 
as compared to sham-operated males (to 74%, 70%, and 
70%, respectively) (Table 1). In contrast, these parameters 
were not changed significantly in CKD females when 
compared to sham-operated females (Table  1). Notably, 
cardiac output was significantly lower in sham-operated 
females than in sham-operated males, corresponding to 
the smaller heart size of females (Table 1). Interestingly, 
Table 1 The effects of sex and CKD on various in vivo left ventricular morphological and cardiac functional parameters
Transthoracic echocardiographic and blood pressure measurements were performed 8 and 9 weeks after 5/6 nephrectomy, respectively. Values are mean ± SEM, 
n = 10–15 for echocardiography (sham male: n = 15, CKD male: n = 11, sham female: n = 10, and CKD female: n = 13), and n = 6–11 for blood pressure measurement 
(sham male: n = 10, CKD male: n = 11, sham female: n = 6, and CKD female: n = 8), *p < 0.05, CKD vs. sham-operated groups, #p < 0.05, females vs. males; p-values refer 
to two-way ANOVA (Holm–Sidak post hoc test). CKD chronic kidney disease, CO cardiac output, d diastolic, DBP diastolic blood pressure, E-wave early ventricular filling 
velocity, e’ e’-wave, mitral annulus velocity measured by tissue Doppler, IWT inferior wall thickness, LVEDD left ventricular end-diastolic diameter, LVEDV left ventricular 
end-diastolic volume, LVESD left ventricular end-systolic diameter, LVESV left ventricular end-systolic volume, PWT posterior wall thickness, s systolic, SBP systolic blood 
pressure, SV stroke volume, SWT septal wall thickness
Parameter (unit) Male Female p‑value
Sham CKD Sham CKD CKD vs. sham Female vs. male
IWTs (mm) 3.07 ± 0.09 3.48 ± 0.21 3.31 ± 0.11 3.67 ± 0.14 0.051 0.373
IWTd (mm) 1.86 ± 0.18 2.42 ± 0.33* 1.72 ± 0.23 2.03 ± 0.09* 0.011 0.066
PWTs (mm) 3.00 ± 0.10 3.42 ± 0.24 3.24 ± 0.12 3.54 ± 0.18 0.089 0.602
PWTd (mm) 1.74 ± 0.05 2.23 ± 0.25* 1.82 ± 0.06 1.97 ± 0.14 0.038 0.203
SWTs (mm) 3.26 ± 0.11 3.98 ± 0.21* 3.32 ± 0.08 3.63 ± 0.12*  < 0.001 0.074
SWTd (mm) 2.02 ± 0.10 2.52 ± 0.18* 1.69 ± 0.08# 1.88 ± 0.07# 0.006  < 0.001
LVEDD (mm) 6.73 ± 0.17 6.50 ± 0.36 6.20 ± 0.14 6.41 ± 0.11 0.547 0.761
LVESD (mm) 3.51 ± 0.17 2.92 ± 0.37 2.15 ± 0.19# 2.07 ± 0.15# 0.182 0.011
Heart rate (1/min) 363 ± 6 347 ± 14 370 ± 12 379 ± 10 0.479 0.045
LVEDV (μL) 102 ± 6 75 ± 6* 89 ± 9 99 ±  6# 0.029 0.031
LVESV (μL) 33 ± 4 26 ± 3 36 ± 4 39 ±  3# 0.377 0.021
SV (μL) 70 ± 4 49 ± 5* 53 ± 6 60 ± 4 0.011 0.120
CO (mL/min) 25 ± 1 17 ± 2* 19 ±  2# 23 ± 1* 0.003 0.013
SBP (mmHg) 111 ± 6 120 ± 4 126 ±  6# 136 ±  8# 0.117 0.017
DBP (mmHg) 87 ± 5 94 ± 4 98 ±  7# 107 ±  8# 0.215 0.048
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left ventricular end-systolic volume was significantly 
increased in CKD in females as compared to males, prob-
ably due to the less severe LVH in females. The heart rate, 
systolic, diastolic, and mean blood pressure were not dif-
ferent in response to CKD in both sexes (Table 1). How-
ever, sham-operated and CKD females had a 12–14% 
higher systolic and diastolic blood pressure than that of 
sham-operated and CKD males, respectively (Table  1). 
Mean blood pressure only showed a tendency to increase 
in sham-operated and CKD females compared to sham-
operated and CKD males, respectively (p = 0.075, 
Fig. 3D). The main systolic functional parameter, ejection 
fraction, did not change significantly between the groups 
(p = 0.559, Fig.  3E). The E- and e’-velocities were meas-
ured by echocardiography to assess the diastolic function 
(Fig.  3F, G). The E- and e’-velocities were significantly 
increased in sham-operated and CKD females compared 
to sham-operated and CKD males, respectively (to 113% 
and 142% for E, and 130% and 160% for e’, respectively) 
(#p < 0.001 for both parameters, Fig. 3F, G). The E velocity 
did not change significantly in response to CKD in either 
sexes (p = 0.560, Fig. 3F). In contrast, e’ was significantly 
reduced in response to CKD in both sexes (to 70% in 
males and 83% in females, *p < 0.001, Fig.  3G), pointing 
out the presence of diastolic dysfunction in CKD.
Fig. 4 The effects of sex on cardiomyocyte hypertrophy, fibrosis and heart failure markers. A Representative hematoxylin–eosin (HE, × 40 
and × 100) and picrosirius red/fast green-stained (PSFG, × 10) sections; B cardiomyocyte perimeter; C left ventricular collagen content; D left 
ventricular A-type natriuretic peptide (ANP) expression; E left ventricular B-type natriuretic peptide (BNP) expression; F circulating plasma BNP level 
measured at week 9. Values are means ± SEM, n = 6–9 for histology (sham male: n = 6, CKD male: n = 9, sham female: n = 6, and CKD female: n = 7), 
n = 7–11 for ANP and BNP expression (sham male: n = 8, CKD male: n = 8, sham female: n = 9, and CKD female: n = 11), and n = 6–7 for circulating 
BNP level (sham male: n = 7, CKD male: n = 6, sham female: n = 6, and CKD female: n = 6), *p < 0.05, CKD vs. sham-operated groups, #p < 0.05, 
females vs. males p-values refer to two-way ANOVA (Holm–Sidak post hoc test)
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Only males develop severe cardiac fibrosis in CKD
To verify the echocardiographic signs of cardiac remod-
eling in CKD, cardiomyocyte perimeter was measured on 
HE-stained slides, while collagen content was assessed 
on PSFG-stained slides (Fig. 4A). Both males and females 
had significantly increased cardiomyocyte perimeters in 
CKD as compared to the sex-matched sham-operated 
groups, proving the development of cardiomyocyte 
hypertrophy at the microscopic level (*p < 0.001, Fig. 4B). 
However, there was no significant sex-based difference in 
the cardiomyocyte perimeters within the CKD or sham-
operated groups (p = 0.086 within sham groups and 
p = 0.219 within the CKD groups, Fig. 4B).
The male CKD group demonstrated significantly 
increased left ventricular collagen content as compared 
to the male sham-operated group, proving the develop-
ment of cardiac fibrosis in CKD (*p < 0.001, Fig.  4). In 
contrast, there was no significant difference in the left 
ventricular collagen content between the female sham-
operated and CKD groups, pointing out a less severe car-
diac remodeling in females in CKD (p = 0.333, Fig.  4C). 
Notably, the left ventricular collagen content was signifi-
cantly reduced in the female CKD group as compared to 
the male CKD group (#p = 0.001). There was no differ-
ence in the collagen content between males and females 
in the sham-operated groups (p = 0.671, Fig. 4C).
Increased left ventricular ANP expression in CKD in both sexes
Left ventricular ANP and BNP expressions as well as cir-
culating BNP levels were measured as myocardial stretch 
markers. The left ventricular ANP expression was signifi-
cantly increased in both sexes in CKD as compared to the 
sex-matched sham-operated groups (p = 0.018, Fig. 4D). 
There was no significant sex-based difference in the left 
ventricular ANP expression within the sham-operated 
or CKD groups (Fig.  4D). Interestingly, there were no 
significant differences in the left ventricular BNP expres-
sion and plasma BNP level between the groups (Fig. 4E, 
F). Notably, plasma BNP level in the female CKD group 
was half of the value of the male CKD group (p = 0.067, 
Fig. 4F), suggesting a less severe uremic cardiomyopathy 
in females.
Effects of sex and CKD on ex vivo morphological 
and functional parameters
Morphological parameters including body weight, tibia 
length, heart weight, left ventricular weight, left kid-
ney weight, and lungs’ weight, were measured at week 
9 to investigate whether CKD influences ex vivo param-
eters similarly in both sexes. The body weight and tibia 
length of females were significantly lower both in sham-
operated (55% and 89%, respectively) and CKD females 
(56% and 89%, respectively) compared to sham-operated 
and CKD males, respectively (Table 2). Both CKD males 
and females had significantly lower body weight (92% and 
95%, respectively) and tibia length (98% and 97%, respec-
tively) as compared to sham-operated males and females 
(Table 2), indicating the development of uremic cachexia 
of similar severity in both sexes. Heart weight, left ven-
tricular weight, lungs’ weight, and kidney weights were 
significantly lower in females than in males irrespective 
of CKD due to the smaller body size of females (Table 2). 
In response to CKD, heart weight showed a trend toward 
an increase in both sexes compared to sham-operated 
animals (Table  2). Left ventricular weights were signifi-
cantly increased in CKD both in males and females (to 
109% and 114%, respectively) compared to sham-oper-
ated males and females, respectively, confirming the 
development of LVH (Table  2). Notably, lungs’ weight 
was slightly increased only in male CKD rats (to 111%), 
but not in female CKD rats, compared to sham-operated 
sex-matched animals, indicating the development of 
Table 2 The effects of sex and CKD on ex vivo heart weights, tibia length, and basal coronary flow
Values are mean ± SEM, n = 30–55 for body weight, heart weight and CF10’ (sham male: n = 35, CKD male: n = 31, sham female: n = 30, and CKD female: n = 55), and 
n = 13–19 for tibia length, LV weight, kidney weight and lung weight (sham male: n = 19, CKD male: n = 13, sham female: n = 18, and CKD female: n = 18), *p < 0.05, 
CKD vs. sham-operated groups, #p < 0.05, females vs. males, respectively, p-values refer to two-way ANOVA (Holm–Sidak post hoc test). CF10’ coronary flow collected 
at the 10th minute or perfusion protocol, CKD chronic kidney disease, LV left ventricular
Parameter (unit) Male Female p‑value
Sham CKD Sham CKD CKD vs. sham Female vs. male
Body weight (g) 488 ± 8 451 ± 7* 268 ±  4# 254 ± 3*#  < 0.001  < 0.001
Tibia length (cm) 4.27 ± 0.03 4.18 ± 0.06* 3.82 ± 0.04# 3.73 ± 0.03*# 0.049  < 0.001
Heart weight (mg) 2450 ± 68 2541 ± 63 1476 ±  34# 1536 ±  32# 0.210  < 0.001
LV weight (mg) 1319 ± 34 1434 ± 49* 900 ±  33# 1023 ± 34*# 0.005  < 0.001
CF10’ (mL/min) 17.5 ± 0.8 17.4 ± 1.0 11.0 ± 0.4# 12.1 ± 0.4# 0.720  < 0.001
Kidney weight (mg) 1330 ± 43 1809 ± 79 989 ±  50# 1189 ± 75 N/A  < 0.001
Lung weight (mg) 1596 ± 55 1765 ± 67 1508 ±  36# 1464 ±  37# 0.242  < 0.001
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mild pulmonary congestion and more severe uremic car-
diomyopathy in males than in females. Interestingly, the 
whole left kidney’s weight in the sham-operated males 
and females were markedly higher than the weight of 
remaining one-third of the left kidney in the CKD males 
and females (136% and 120%, respectively), suggesting a 
frank compensatory renal hypertrophy in the CKD ani-
mals (Table 2).
Selection of the female rats before heart perfusion 
protocols based on vaginal smear investigation
The fluctuation of estrogen and progesterone levels 
during the menstrual cycle may acutely influence the 
infarct size and cardiac protein expression patterns. 
Therefore, female rats were selected 12  h before the 
heart perfusion protocols according to their menstrual 
cycle as assessed by vaginal smear investigation. In the 
pro-estrus phase, many nucleated spherical epithe-
lial cells could be present, which is the regeneration 
Fig. 5 The effects of sex and CKD on the cardioprotection conferred by IPRE. A Representative images of the estrus cycle in female rats; B 
representative images of myocardial infarction stained by triphenyl-tetrazolium chloride (TTC), and C infarct size (IS). Values are means ± SEM, 
n = 8–8 in males (in every subgroup) and n = 9–19 in females (sham I/R: n = 9, sham IPRE + I/R: n = 10, CKD I/R: n = 19, and CKD IPRE + I/R: n = 19) 
for IS, *p < 0.05, IPRE + I/R vs. I/R subgroups, #p < 0.05, females vs. males, p-values refer to three-way ANOVA (Holm–Sidak post hoc test). CKD chronic 
kidney disease, IPRE ischemic preconditioning, I/R ischemia/reperfusion
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phase of the vaginal epithelia, followed by ovulation 
(Fig. 5A). After ovulation, nucleated cornified epithelial 
cells could be observed in the estrus phase (Fig.  5A). 
As the epithelia degenerate, lymphocytes become more 
dominant in the smear, known as the met-estrus phase 
(Fig.  5A). In this phase, the same proportion among 
leukocytes, cornified, and nucleated epithelial cells 
could be present. This phase is followed by the total 
degradation of the vaginal epithelia in the resting part 
of the cycle, called the di-estrus phase. In this phase, 
the cytologic slide could be very poor in cells; just a few 
epithelial cells without a nucleus and some lympho-
cytes can be found (Fig.  5A). We selected the female 
rats for heart perfusion in the di-estrus phase, in which 
the estrogen and progesterone levels are considered the 
lowest [38].
Ischemic preconditioning reduced the infarct size 
in both sexes irrespective of CKD
Infarct size was measured at week 9 to investigate the 
severity of I/R injury and the cardioprotective effect of 
IPRE in both sexes in CKD (Fig. 5B). Additionally, the 
coronary flow was measured 10  min after the cannu-
lation of the hearts (coronary flow at 10 min [CF10’]), 
immediately after the global ischemia (CF80’), and at 
the end of the 2  h reperfusion (CF200’) to assess the 
ex  vivo cardiac function (Figs.  1, 5C, and Additional 
file  1: Fig. S1A and 1B). The coronary flow at 10  min 
was similar in sham-operated and CKD animals of 
the same sex (Table  2), indicating no basal differences 
in the contractile function in response to CKD, which 
supports the echocardiographic results. Notably, CF10’ 
values were significantly lower in sham-operated and 
CKD females than in sham-operated and CKD males 
(63% and 70%, respectively) due to the smaller heart 
size of females vs. males (Table  2). The CF80’ values 
were significantly smaller in sham-operated females 
in the I/R subgroup than in the sham-operated males 
in the I/R subgroup due to the smaller heart size of 
females (#p = 0.049, Additional file  1: Fig. S1A). There 
was no significant difference in the CF80’ values 
between CKD males and females in the I/R subgroup 
(Additional file  1: Fig. S1A). However, CKD males in 
the I/R subgroups had significantly decreased CF80’ 
values compared to sham-operated males in the I/R 
subgroup (†p = 0.002, Additional file 1: Fig. S1A). Inter-
estingly, IPRE significantly increased the CF80’ val-
ues in sham-operated and CKD males and females (to 
150%, 163%, 135%, and 130%, respectively) (*p < 0.001, 
Additional file 1: Fig. S1A). The CF200’ values showed a 
similar pattern than the CF80’ values (Additional file 1: 
Fig. S1B). The only difference was that IPRE could not 
significantly increase the CF200’ value in the female 
CKD group as compared to the female sham-operated 
group (Additional file 1: Fig. S1B).
Similarly to the CF80’ values, IPRE significantly 
decreased infarct size in sham-operated and CKD males 
and females (to 60%, 55%, 55%, and 73%, respectively) 
(*p < 0.001, Fig.  5C); however, the presence of CKD did 
not significantly influence the size of infarction in either 
sexes (p = 0.294, Fig.  5C). Notably, the infarct size was 
significantly smaller in both sham-operated and CKD 
females in the I/R subgroups compared to sham-operated 
and CKD males in the I/R subgroups (#p < 0.001, 68% and 
58%, respectively), indicating a marked cardioprotective 
effect of the female sex irrespective of CKD (Fig. 5C).
The potential role of the SAFE and RISK pathways 
in the cardioprotective effect of IPRE in CKD in both sexes
At the end of reperfusion, a subgroup of hearts was col-
lected for molecular measurements at the protein level 
(Fig. 6, Additional file 2: Fig. S2, Additional file 3: Fig. S3, 
Additional file 4: Fig. S4, Additional file 5: Fig. S5, Addi-
tional file 6: Fig. S6, Additional file 7: Fig. S7, Additional 
file  8: Fig. S8). Total proteins and their phosphorylated 
forms related to the cardioprotective SAFE (STAT3) and 
RISK (AKT, ERK1,2) pathways were measured by West-
ern blot (Fig. 6, and Additional file 2: Fig. S2, Additional 
file 3: Fig. S3, Additional file 4: Fig. S4, Additional file 5: 
Fig. S5, Additional file 6: Fig. S6, Additional file 7: Fig. S7). 
IPRE significantly increased the phospho-STAT3/STAT3 
ratio in sham-operated males and females compared 
to sex-matched sham-operated I/R subgroups, respec-
tively (*p = 0.004, Fig.  6A). IPRE failed to significantly 
change the phospho-STAT3/STAT3 in CKD males and 
females compared to sex-matched CKD I/R subgroups, 
respectively (p = 0.094, Fig.  6A). In the female sham-
operated I/R and preconditioned subgroups, the phos-
pho-STAT3/STAT3 ratio was significantly lower than 
in the sham-operated male I/R and preconditioned sub-
groups, respectively (#p = 0.026, Fig. 6A). CKD abolished 
these lowering effects of the female sex on the phospho-
STAT3/STAT3 ratio in the I/R and preconditioned sub-
groups compared to male I/R and preconditioned CKD 
subgroups, respectively (p = 0.164, Fig. 6A). Interestingly, 
the phospho-STAT3/STAT3 ratio was significantly higher 
in CKD males and females in the I/R subgroups com-
pared to the sham-operated sex-matched I/R subgroups, 
respectively (†p = 0.025, Fig.  6A). This increasing effect 
of CKD on the phospho-STAT3/STAT3 ratio was not 
detectable in the preconditioned hearts as compared to 
sham-operated preconditioned subgroups in both sexes 
(p = 0.154, Fig. 6A). In phosho-AKT/AKT and phospho-
ERK1,2/ERK1,2 ratios, there were no significant differ-
ences between the groups (Fig. 6B-6D).
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Discussion
We have found here that, although 9 weeks of experimen-
tal CKD leads to severe changes in metabolic parameters 
as well as myocardial morphology and function, the car-
dioprotective effect of ischemic preconditioning is pre-
served in both sexes. This is the first demonstration that 
CKD does not interfere with the cardioprotective effect 
of ischemic preconditioning in the female sex.
5/6 nephrectomy is probably the most established 
model of progressive renal failure mimicking the con-
sequences of the reduction of functional nephron num-
ber [39, 40]. Our present findings are consistent with 
the literature data and our previous results in male 5/6 
nephrectomy-induced CKD rats [28, 29, 39]. Here, 
we have found characteristic laboratory signs of CKD, 
including increased serum urea and creatinine concen-
trations and urine protein levels and diminished creati-
nine clearance with uremic cachexia in both sexes. Based 
on serum urea and creatinine levels as well as creati-
nine clearance normalized to percent changes, male and 
female rats developed CKD of similar severity 9  weeks 
after 5/6 nephrectomy. Among the routine laboratory 
parameters of CKD, only proteinuria was more severe in 
males compared to females in our present study, which 
Fig. 6 The effects of sex and CKD on the activation by phosphorylation of STAT3, AKT, and ERK1/2. A Phospho-STAT3/STAT3 ratios; B phospho-AKT/
AKT ratios; C phospho-ERK1/ERK1 ratios; D phospho-ERK2/ERK2 ratios. Values are means ± SEM, n = 5–7 (male sham I/R: n = 5, male sham IPRE + I/R: 
n = 6, male CKD I/R: n = 6, male CKD IPRE + I/R: n = 5, female sham I/R: n = 6, female sham IPRE + I/R: n = 7, female CKD I/R: n = 7, and female CKD 
IPRE + I/R: n = 5), *p < 0.05, IPRE + I/R vs. I/R subgroups, #p < 0.05, females vs. males, †p < 0.05, CKD vs. sham-operated groups, p-values refer to 
three-way ANOVA (Holm–Sidak post hoc test). CKD chronic kidney disease, IPRE ischemic preconditioning, I/R ischemia/reperfusion. Bands on the 
representative Western blot images correspond to the groups represented by bar graphs: 1. male sham I/R, 2. male sham IPRE + I/R, 3. male CKD I/R, 
4. male CKD IPRE + I/R, 5. female sham I/R, 6. female sham IPRE + I/R, 7. female CKD I/R, 8. female CKD IPRE + I/R. Representative bands are framed on 
the original and uncropped images in Additional file 2: Fig. S2, Additional file 3: Fig. S3, Additional file 4: Fig. S4
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is consistent with the findings of Lemos et al. using 5/6 
nephrectomy in male and female Wistar rats to induce 
CKD [41]. Serum cholesterol levels were significantly 
higher in both sexes, pointing out the role of CKD in 
increased cardiovascular risk in both sexes [10]. Interest-
ingly, serum triglyceride levels were significantly lower 
in females than in males independently of CKD, suggest-
ing the cardiovascular risk lowering effect of the female 
sex; however, the precise molecular mechanism is yet 
unknown.
Both the Framingham Heart Study and Multi-Ethnic 
Study of Atherosclerosis demonstrated that left ventricu-
lar mass and volume are significantly greater in healthy 
men compared to women, even after adjusting for height 
and body surface area [42, 43]. These sex-based differ-
ences in the heart size are clearly seen in our present 
study in the heart weight, left ventricular weight, several 
wall thicknesses including anterior and septal wall thick-
nesses, left ventricular end-systolic diameter and cardiac 
output in the sham-operated animals. Premenopausal 
status in women is strongly related to better diastolic 
function and postmenopausal status is associated with 
accelerated age-related impairments in left ventricular 
relaxation [43]. Indeed, estrogen is described as a direct 
vasodilator and it could promote nitric oxide excretion, 
and directly improve myocardial calcium ion handling. 
All of these factors could improve the diastolic function 
in females [43]. In accordance with the aforementioned 
clinical findings and potential mechanisms, the diastolic 
parameters e’ and E velocities were significantly higher in 
females than in males in the sham-operated group in our 
present study.
In CKD patients, uremic cardiomyopathy is a com-
mon complication and reported to be a prognostic fac-
tor of cardiovascular mortality [10]. In our CKD model, 
marked cardiac morphological and functional changes 
were confirmed by echocardiography 8  weeks after the 
5/6 nephrectomy. In our present study, male animals 
developed LVH with diastolic dysfunction and fibrosis 
as signs of uremic cardiomyopathy. We and others have 
previously shown that male CKD rats developed cardiac 
hypertrophy and fibrosis 9 or 12 weeks after 5/6 nephrec-
tomy [29, 44, 45] which is consistent with our present 
results in male rats. However, there are only a very lim-
ited number of studies in the literature comparing the 
severity of cardiac hypertrophy and fibrosis between 
males and females in CKD induced by 5/6 nephrec-
tomy [45, 46]. In the study of Paterson et  al., there was 
no difference in the left ventricular collagen content 
between sham-operated and 5/6 nephrectomy-induced 
CKD groups in female rats 7 weeks after the operations 
[45]. However, cardiac fibrosis showed a trend toward a 
decrease in the female CKD group when compared to the 
male CKD group in their study [45]. These results of Pat-
erson et al. are similar to our present findings on statisti-
cally significant sex-based differences in cardiac fibrosis 
in CKD.
Severe hypertension is not usually a feature of the 5/6 
nephrectomy-induced CKD models [39, 47]. Accord-
ingly, the blood pressure was not significantly altered in 
CKD in either sex in our present study. Therefore, dias-
tolic dysfunction might be developed as a direct con-
sequence of LVH and cardiac fibrosis without severe 
hypertension in our CKD model. In our present study, 
female CKD rats developed a less severe LVH and dias-
tolic dysfunction without cardiac fibrosis. An expla-
nation for the less severe uremic cardiomyopathy in 
females could be the protective effects of estrogen via 
estrogen receptor-beta mediated anti-oxidative, anti-
inflammatory and anti-apoptotic mechanisms [48, 49]. 
Further explanation could be that several genes related to 
adverse cardiac remodeling such as macrophage activa-
tion in the inflammatory processes, apoptosis, and lipid 
metabolism are located on the Y chromosome [48, 50]. 
Next to that, the quantity of viable cardiomyocytes in the 
healthy aging male heart decreases more rapidly than in 
the female heart, making the male heart already more 
prone to hypertrophy and stress [43, 48, 51]. In summary, 
our present echocardiographic and histologic findings 
on sex-based differences in the development of uremic 
cardiomyopathy are consistent with clinical observations 
that pre-menopausal women have a lower risk of devel-
oping LVH and cardiac remodeling [52].
To strengthen our echocardiographic and histologic 
results, we measured the left ventricular expression of 
ANP and BNP and the circulating BNP levels as myo-
cardial stretch and heart failure markers [53]. ANP and 
BNP are released upon stimulation by stretching of the 
atrial and ventricular cardiomyocytes (e.g., overfilled 
heart), thereby causing natriuresis and diuresis, vasodi-
lation and inhibition of the renin–angiotensin–aldoster-
one and sympathetic nervous system [54]. In our present 
study, left ventricular ANP expression was significantly 
increased in response to CKD independently of sex. In 
contrast, there was no significant difference between the 
groups in the left ventricular BNP expression and circu-
lating BNP level. Notably, the circulating BNP level in 
females was half of the value of males in CKD suggesting 
a less severe cardiac remodeling in females than in males. 
These results are in accordance with our echocardio-
graphic and histologic results.
The lack of severe hypertension and atherosclerosis 
in our CKD model makes it possible to study the direct 
effects of CKD on uremic cardiomyopathy and AMI. 
While traditional cardiovascular risk factors such as 
hypertension, atherosclerosis, and diabetes mellitus, are 
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highly prevalent in CKD patients, results of clinical tri-
als focusing on controlling these traditional cardiovas-
cular risk factors have been mostly disappointing [39]. 
Both pre-clinical and clinical studies showed that CKD-
specific risk factors such as uremic toxins, renal anemia, 
the over-activation of the renin–angiotensin–aldosterone 
system and sympathetic nervous system with increased 
oxidative/nitrative/nitrosative stress and decreased nitric 
oxide levels could provoke the development of uremic 
cardiomyopathy and increase the burden of AMI regard-
less of pressure- and volume overload [10].
CKD is a recognized risk multiplier for the develop-
ment of CVDs [10], and AMI is a common cause of death 
in CKD [7]. A large body of evidence showed that cardiac 
conditioning strategies such as ischemic preconditioning, 
postconditioning, and remote conditioning are cardio-
protective and significantly reduce myocardial I/R injury 
under experimental conditions [55]. Unfortunately, the 
clinical translation of cardioprotection by ischemic con-
ditioning has been mostly disappointing. This unsuccess-
ful clinical translation of ischemic conditioning strategies 
might be explained by the differences between pre-clin-
ical models and the clinical scenario in AMI patients, 
including age, concomitant treatments, cardiovascular 
risk factors, and co-morbidities, such as aging, diabe-
tes mellitus, and hyperlipidemia [56]. Moreover, unified 
recruitment strategies and algorithms of the condition-
ing stimulus, including the duration and number of I/R 
cycles, and its temporal distance to the index ischemia, 
are still lacking in the clinical phase trials [16].
Unfortunately, CKD patients are regularly excluded 
from clinical trials. However, we and others have previ-
ously shown that IPRE is cardioprotective in male rats in 
subacute and chronic renal failure, despite the complex 
changes in the systemic metabolism, including hypercho-
lesterolemia and cardiac morphology and function [25, 
28]. Therefore, CKD patients may also benefit from car-
dioprotection by ischemic conditioning strategies. This 
is particularly important since AMI frequently occurs 
in CKD patients. Interestingly, pre-clinical studies have 
shown that IPRE also remains cardioprotective in LVH 
[57] and hypertension [58, 59]. Therefore, we believe that 
the presence of LVH and diastolic dysfunction in CKD 
animals might not interfere with the cardioprotective 
effects of IPRE. However, it cannot be excluded that the 
cardioprotection by IPRE may be lost with the progres-
sion of CKD and the development of severe heart failure 
with reduced ejection fraction, as it has been reported 
that endogenous cardioprotection is lost in severe heart 
failure [24, 60, 61].
Epidemiological studies have shown that pre-menopau-
sal women have a lower incidence of coronary artery dis-
ease than age-matched men [52, 62]. Pre-clinical studies 
have also shown that female animals have reduced I/R 
injury [63–66]. In this aspect, our infarct size results 
in females are in line with the literature data. However, 
due to the higher ischemic tolerance, the female sex is a 
potential confounder of ischemic conditioning interven-
tions. Experimental studies dealing with this problem are 
sporadic and not conclusive, and clinical observations are 
mostly missing. In those limited number of studies com-
paring cardioprotection between both sexes, ischemic 
conditioning decreased the infarct size less in female 
than in male rat hearts [67, 68]. In our present study, the 
smaller reduction of the infarct size by ischemic condi-
tioning in females compared to males is similar to the lit-
erature data. The menstrual cycle in female rats is short 
(4–5 days), and therefore several studies claimed that the 
acute fluctuation of estrogen and progesterone levels did 
not influence the myocardial ischemia/reperfusion injury 
[69]. In contrast, others showed that acute estrogen (i.e., 
17β-estradiol) administration reduces the infarct size via 
reduction of mitophagy and the activation of the MEK/
ERK/GSK-3β axis [70]. Therefore, we selected the female 
rats respecting the phase of their menstrual cycle before 
the perfusion protocols to eliminate the potential effects 
of fluctuating estrogen levels leading to inconclusive 
results in the infarct size.
In our current study, we also attempted to find possible 
downstream mechanisms of IPRE to relate the infarct size 
results with well-known cardioprotective mechanisms. 
Two major intracellular signaling pathways are consid-
ered as mediators of the IPRE stimulus, (i) the SAFE and 
(ii) RISK pathways [16]. STAT3 is considered a key com-
ponent of the SAFE pathway, and AKT and ERK1,2 are 
believed to be the central mediators of the RISK path-
way [16, 71]. We have assessed phosphorylation rates of 
STAT3, AKT, and ERK1,2 at the end of reperfusion, as 
infarct size analysis was performed at that time-point 
in our present study. We have shown here that 3 cycles 
of IPRE are associated with a significant increase in the 
phospho-STAT3/STAT3 ratio in the sham-operated 
animals 2 h after the end of the index ischemia in both 
sexes, which is in line with the literature data despite the 
late time-point [72]. In the sham-operated groups, IPRE 
failed to increase the phosphorylation of either AKT or 
ERK1,2 proteins significantly, respectively. This seems 
to be in contrast to some literature data and the general 
concept that the RISK pathway is a primary contributor 
to the cardioprotective effects of IPRE. This discrepancy 
might be explained by the experimental protocol that we 
used. We measured kinase phosphorylations 2 h after the 
end of the index ischemia. However, the phosphorylation 
status of IPRE-related kinases is mostly investigated at 
earlier time-points at the beginning of reperfusion. Nev-
ertheless, several studies have already reported the later 
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activation of cardiac SAFE and RISK pathways after 30, 
120, or 180  min of reperfusion in response to ischemic 
conditionings [71, 73, 74].
In contrast with the findings by Byrne et al., the phos-
pho-STAT3/STAT3 ratio failed to increase in male CKD 
rats in our present study. Our controversial result might 
be explained by the fact that Byrne et al. investigated the 
phosphorylation of STAT3 in an earlier and less severe 
phase of kidney disease and uremic cardiomyopathy 
(i.e., 4 weeks after the 5/6 nephrectomy). Another poten-
tial explanation is the previous activation of STAT3 in 
response to CKD in both sexes. Therefore, IPRE might be 
unable to increase the activation of STAT3 in CKD fur-
ther. Notably, STAT3 is also a hypertrophy-inducing mol-
ecule [72], and LVH was confirmed in CKD in both sexes. 
Moreover, renal failure and the development of uremic 
cardiomyopathy also seem to interact with other protein 
kinases such as ERK1,2 and AKT, which activations are 
suggested to be involved in the mechanism of IPRE [29, 
75, 76]. However, our present findings do not exclude the 
possible activation of the RISK and/or SAFE pathways 
by IPRE in earlier time-points of the reperfusion of the 
protocol that we used in sham-operated and/or CKD ani-
mals in both sexes.
Limitations
Our study is not without limitations, similar to other 
experimental works. We have analyzed the infarct size 
and the SAFE and RISK pathways at a single time-point 
(i.e., 2  h after the end of the index ischemia). This fact 
might limit the proper interpretation of the early-phase 
molecular changes in the course of cardioprotection by 
IPRE. Therefore, investigation of the expression and 
activity of survival kinases in the SAFE and RISK path-
ways at earlier time-points might have some added value 
for our study. A common feature of experimental studies 
performed on I/R and conditioning strategies is that the 
ischemic cardiac tissue may contain viable and non-via-
ble cells. The lack of separation of the viable and non-via-
ble cells may affect the molecular markers in biochemical 
analyses leading to the blurring of results. The interpreta-
tion of these results could be a major problem, especially 
in studies using regional ischemia, because it is almost 
impossible to separate the non-ischemic, ischemic-viable, 
and ischemic-non-viable cells. Therefore, in our present 
study, we used global ischemia to expose all cardiac cells 
to the same ischemic stress. Despite these limitations, 
our study provides valuable data on the effect of experi-
mental CKD on the infarct size-limiting effect and poten-
tial molecular mechanisms of ischemic preconditioning.
Perspectives and significance
Taken together, males developed a more severe uremic 
cardiomyopathy in CKD than females. However, we have 
demonstrated for the first time in the present study, that 
the cardioprotective effect of IPRE is preserved in CKD 
in both sexes, even if CKD is associated with various 
structural, functional, and metabolic changes of the myo-
cardium. The reason why the complex metabolic changes 
of CKD do not affect the overall efficacy of cardioprotec-
tion by IPRE is unknown. This result is exciting because 
several metabolic diseases, including diabetes mellitus 
and hyperlipidemia, abolish the endogenous cardiopro-
tective mechanisms of ischemic conditioning strategies. 
Our present study suggests that CKD patients also ben-
efit from cardioprotective strategies such as ischemic 
preconditioning regardless of their sex. Future pre-clin-
ical studies investigating the molecular mechanisms of 
ischemic conditioning strategies in CKD in both sexes 
are needed. There is also an urgent need for clinical trials 
to investigate the cardioprotective effect of conditioning 
strategies in CKD patients of both sexes suffering from 
AMI.
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Additional file 1: Fig. S1. Coronary flow at the  80th and  200th minutes of 
the perfusion protocol. (A) coronary flow at the  80th minute of the perfu-
sion (CF80’) and (B) coronary flow at the  200th minute of the perfusion 
(CF200’). Values are means ± SEM, n = 15–18 in males (sham I/R: n = 17, 
sham IPRE + I/R: n = 18, CKD I/R: n = 15, and CKD IPRE + I/R: n = 16) and 
n = 15–28 in females (sham I/R: n = 15, sham IPRE + I/R: n = 15, CKD I/R: 
n = 27, and CKD IPRE + I/R: n = 28). *p < 0.05, IPRE + I/R vs. I/R subgroups, 
#p < 0.05, females vs. males, †p < 0.05, CKD vs. sham-operated groups, 
p-values refer to three-way ANOVA (Holm–Sidak post hoc test). CKD: 
chronic kidney disease, IPRE: ischemic preconditioning, I/R: ischemia/
reperfusion.
Additional file 2: Fig. S2. Original uncropped and unmodified Western 
blot images. Representative bands used in Fig. 6 are framed.
Additional file 3: Fig. S3. Original uncropped and unmodified Western 
blot images. Representative bands used in Fig. 6 are framed.
Additional file 4: Fig. S4. Original uncropped and unmodified Western 
blot images. Representative bands used in Fig. 6 are framed.
Additional file 5: Fig. S5. Western blot results: phospho-STAT3/GAPDH 
and STAT3/GAPDH ratios. (A) Representative Western blot images, (B) 
phospho-STAT3/GAPDH ratios, (C) STAT3/GAPDH ratios. Values are 
means ± SEM, n = 5–7 (male sham I/R: n = 5, male sham IPRE + I/R: n = 6, 
male CKD I/R: n = 6, male CKD IPRE + I/R: n = 5, female sham I/R: n = 6, 
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female sham IPRE + I/R: n = 7, female CKD I/R: n = 7, and female CKD 
IPRE + I/R: n = 5), *p < 0.05, CKD vs. sham-operated groups, #p < 0.05, 
females vs. males, p-values refer to three-way ANOVA (Holm–Sidak post 
hoc test). CKD: chronic kidney disease, IPRE: ischemic preconditioning, I/R: 
ischemia/reperfusion.
Additional file 6: Fig. S6. Western blot results: phospho-AKT/GAPDH and 
AKT/GAPDH ratios. (A) Representative Western blot images, (B) phospho-
AKT/GAPDH ratios, (C) AKT/GAPDH ratios. Values are means ± SEM, 
n = 5–7 (male sham I/R: n = 5, male sham IPRE + I/R: n = 6, male CKD I/R: 
n = 6, male CKD IPRE + I/R: n = 5, female sham I/R: n = 6, female sham 
IPRE + I/R: n = 7, female CKD I/R: n = 7, and female CKD IPRE + I/R: n = 5), 
*p < 0.05, CKD vs. sham-operated groups, #p < 0.05, females vs. males, 
p-values refer to three-way ANOVA (Holm–Sidak post hoc test). CKD: 
chronic kidney disease, IPRE: ischemic preconditioning, I/R: ischemia/
reperfusion.
Additional file 7: Fig. S7. Western blot results: phospho-ERK1/GAPDH 
and ERK1/GAPDH ratios. (A) Representative Western blot images, (B) phos-
pho-ERK1/GAPDH ratios, (C) ERK1/GAPDH ratios. Values are means ± SEM, 
n = 5–7 (male sham I/R: n = 5, male sham IPRE + I/R: n = 6, male CKD I/R: 
n = 6, male CKD IPRE + I/R: n = 5, female sham I/R: n = 6, female sham 
IPRE + I/R: n = 7, female CKD I/R: n = 7, and female CKD IPRE + I/R: n = 5), 
*p < 0.05, CKD vs. sham-operated groups, #p < 0.05, females vs. males, 
p-values refer to three-way ANOVA (Holm–Sidak post hoc test). CKD: 
chronic kidney disease, IPRE: ischemic preconditioning, I/R: ischemia/
reperfusion.
Additional file 8: Fig. S8. Western blot results: phospho-ERK2/GAPDH 
and ERK2/GAPDH ratios. (A) Representative Western blot images, (B) phos-
pho-ERK2/GAPDH ratios, (C) ERK2/GAPDH ratios. Values are means ± SEM, 
n = 5–7 (male sham I/R: n = 5, male sham IPRE + I/R: n = 6, male CKD I/R: 
n = 6, male CKD IPRE + I/R: n = 5, female sham I/R: n = 6, female sham 
IPRE + I/R: n = 7, female CKD I/R: n = 7, and female CKD IPRE + I/R: n = 5), 
*p < 0.05, CKD vs. sham-operated groups, #p < 0.05, females vs. males, 
p-values refer to three-way ANOVA (Holm–Sidak post hoc test). CKD: 
chronic kidney disease, IPRE: ischemic preconditioning, I/R: ischemia/
reperfusion.
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